Nuvectis Pharma Inc Market Cap ($626.11 Million)
Market Cap & Net Worth: Nuvectis Pharma Inc (NVCT)
Nuvectis Pharma Inc market cap. Nuvectis Pharma Inc (NASDAQ:NVCT) has a market capitalization of $626.11 Million ($626.11 Million) as of November 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #10787 globally and #2853 in its home market, demonstrating a -4.34% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nuvectis Pharma Inc's stock price $19.18 by its total outstanding shares 32644066 (32.64 Million). Also see Nuvectis Pharma Inc cash conversion from operations for how efficiently the company converts equity into cash flow.
Nuvectis Pharma Inc Market Cap History (2022–2026)
Nuvectis Pharma Inc market cap history from 2022 to 2026. Data shows growth from $244.83 Million to $626.11 Million (45.37% CAGR). Check Nuvectis Pharma Inc (NVCT) stock price for real-time trading data and today's change.
Index Memberships
Nuvectis Pharma Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.60 Trillion | 0.02% | #296 of 976 |
|
NASDAQ Composite
IXIC
|
$39.84 Trillion | 0.00% | #1109 of 3165 |
Weight: Nuvectis Pharma Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Nuvectis Pharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nuvectis Pharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Nuvectis Pharma Inc to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1643.16x
Nuvectis Pharma Inc's market cap is 1643.16 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $244.83 Million | $149.00K | -$18.79 Million | 1643.16x | N/A |
Competitor Companies of NVCT by Market Capitalization
Companies near Nuvectis Pharma Inc in the global market cap rankings as of November 3, 2026. Also see balance sheet size of Nuvectis Pharma Inc for a full breakdown of the balance sheet.
Key companies related to Nuvectis Pharma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Nuvectis Pharma Inc (2022–2026)
Market capitalization of Nuvectis Pharma Inc from 2022 to today. Between 2022 and today, Nuvectis Pharma Inc's market cap moved from $244.83 Million to $ 626.11 Million, with a yearly change of 45.37%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $626.11 Million | +154.04% |
| 2025 | $246.46 Million | +39.56% |
| 2024 | $176.60 Million | -35.13% |
| 2023 | $272.25 Million | +11.20% |
| 2022 | $244.83 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Nuvectis Pharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $626.11 Million USD |
| MoneyControl | $626.11 Million USD |
| MarketWatch | $626.11 Million USD |
| marketcap.company | $626.11 Million USD |
| Reuters | $626.11 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nuvectis Pharma Inc
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was forme… Read more